Though recent effort in risk stratification and intensified chemotherapy and stem cell transplantation improved clinical outcome to a certain extent [6,7] treatment resistance of MLL-ALL and MLL-AML has been one of the critical issues to be addressed [8]. The gene discussed is KMT2A; the disease is acute myeloid leukemia.